Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/1758834015572343 http://scihub22266oqcxt.onion/10.1177/1758834015572343 C4406914!4406914!26673925     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ther+Adv+Med+Oncol 2015 ; 7 (3): 153-69 Nephropedia Template TP {{tp|p=26673925|t=2015. Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review |pdf=|usr=}}{{26673925}} gab.com Text Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review JO: Ther Adv Med Oncol http://www.kidney.de/pget.php?&tw=1&pmid=26673925 #FOAvip Systemic therapy is the standard care for patients with unresectable advanced colorectal cancer (CRC), but salvage surgery of metastatic disease should be considered in the case of adequate tumor shrinkage. Several drugs and combinations are now available for use in treating patients with advanced CRC, but the optimal sequence of therapy remains unknown. Moreover, the administration of antitumor therapy can be modulated by periods of maintenance or treatment breaks rather than delivered as full therapy until disease progression or unacceptable toxicity, followed by reintroduction of prior full therapy when required, before switching to other drugs. Consequently, randomized strategy trials are needed to define the optimal treatment sequences. Molecular testing for Kirsten rat sarcoma viral oncogene homolog (KRAS) and neuroblastoma RAS viral oncogene homolog (NRAS) is mandatory but not sufficient to select appropriate patients for epidermal growth factor receptor (EGFR) monoclonal antibody (MoAb) therapy. Twit Text FOAVip Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review ????Ther Adv Med Oncol http://www.kidney.de/pget.php?&tw=1&pmid=26673925 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26673925 #FOAvip English Wikipedia <ref>{{Cite pmid|26673925}}</ref> Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review #MMPMID26673925 Chibaudel B; Tournigand C; Bonnetain F; Richa H; Benetkiewicz M; André T; de Gramont A Ther Adv Med Oncol 2015[May]; 7 (3): 153-69 PMID26673925show ga Systemic therapy is the standard care for patients with unresectable advanced colorectal cancer (CRC), but salvage surgery of metastatic disease should be considered in the case of adequate tumor shrinkage. Several drugs and combinations are now available for use in treating patients with advanced CRC, but the optimal sequence of therapy remains unknown. Moreover, the administration of antitumor therapy can be modulated by periods of maintenance or treatment breaks rather than delivered as full therapy until disease progression or unacceptable toxicity, followed by reintroduction of prior full therapy when required, before switching to other drugs. Consequently, randomized strategy trials are needed to define the optimal treatment sequences. Molecular testing for Kirsten rat sarcoma viral oncogene homolog (KRAS) and neuroblastoma RAS viral oncogene homolog (NRAS) is mandatory but not sufficient to select appropriate patients for epidermal growth factor receptor (EGFR) monoclonal antibody (MoAb) therapy. äTherapeutic strategy in unresectable metastatic colorectal cancer: an (epmc).pdf DeepDyve Pubget Overpricing